Efficacy and Safety of Hepatic Arterial Infusion of Fluorouracil with Leucovorin as Salvage Treatment for Refractory Liver Metastases from Colorectal Cancer.
10.3904/kjim.2011.26.1.82
- Author:
Hyun Jung LEE
1
;
Yoon Soo LEE
;
Keun Wook LEE
;
So Yeon KIM
;
Chang Jin YOON
;
Dong Yeop SHIN
;
Yun Gyoo LEE
;
Se Yeon CHOI
;
Sung Gwon KANG
;
Sung Bum KANG
;
Jee Hyun KIM
Author Information
1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. jhkimmd@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Colorectal neoplasms;
Fluorouracil;
Infusions, intra-arterial;
Leucovorin
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects;
Colorectal Neoplasms/*pathology;
Female;
Fluorouracil/administration & dosage/*therapeutic use;
Humans;
*Infusions, Intra-Arterial;
Leucovorin/administration & dosage/*therapeutic use;
Liver Neoplasms/*drug therapy/mortality/*secondary;
Male;
Middle Aged;
*Salvage Therapy
- From:The Korean Journal of Internal Medicine
2011;26(1):82-88
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Limited options remain for patients with metastatic colorectal cancer (CRC) after failure of standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI) has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The present study was conducted to evaluate the efficacy and safety of HAI of fluorouracil with leucovorin (HAI 5-FU/LV) for patients with liver metastases from CRC. METHODS: Fourteen patients with liver metastases from CRC who received HAI 5-FU/LV after failure of systemic chemotherapy containing fluorouracil and leucovorin were identified and their medical records were reviewed. RESULTS: Of 10 patients evaluable for response, one partial response, six stable disease, and three progressive disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respectively. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months (range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic toxicities occurred and one case of abdominal pain and two cases of oral mucositis were the only grade 3 nonhematologic toxicities. Catheter-related complications occurred in three patients: one thrombosis, one infection, and one displacement. CONCLUSIONS: HAI 5-FU/LV was well tolerated and showed modest efficacy for patients with liver metastases from refractory CRC. Readministration of previously used chemotherapeutic agents via the hepatic artery could be an effective salvage option and warrants further investigation in a prospective trial.
